What is subcutaneous injection of evantuzumab (Rybrevant Faspro)?

Subcutaneous injection of evantumumab (Rybrevant Faspro) is an innovative anti-cancer drug mainly used to treat certain types of non-small cell lung cancer (NSCLC) , especially those carrying epidermal growth factor receptor (EGFR) mutations. The drug consists of two components: amivantamab (amivantamab) and hyaluronidase. It combines the characteristics of a bispecific antibody and an endoglycosidase to demonstrate excellent therapeutic effects. Specifically, indications for evantumumab include:

1. Use in combination with lazertinib: For first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. These patients need to have EGFR exon 19 deletion or exon 21 L858R substitution mutation, confirmed by an FDA-approved test.

2. Combined treatment with carboplatin and pemetrexed: For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer, provided that the patient has EGFR exon 19 deletion or 21 L858R mutation, and the disease has progressed after treatment with an EGFR tyrosine kinase inhibitor.

3. ForEGFR exon 20 insertion mutations: It can be used in first-line treatment in combination with carboplatin and pemetrexed, and is suitable for patients with locally advanced or metastatic non-small cell lung cancer confirmed by FDA-approved testing.

4. As monotherapy: When patients with locally advanced or metastatic non-small cell lung cancer progress during or after platinum-based chemotherapy and have EGFR exon 20 insertion mutations confirmed by FDA testing, evantumumab can be used for treatment.

Evantumumab is a subcutaneous injection formulation that is more convenient to administer than earlier intravenous infusion forms. Through Halozyme's ENHANZE delivery technology, the drug's administration time has been significantly shortened from hours to minutes, and adverse reactions related to administration have been significantly reduced. Subcutaneous evantumumab, approved by the FDA on December 17, 2025, provides patients with a new treatment option and improves treatment experience and results.

Reference materials:https://www.drugs.com/history/rybrevant-faspro.html